AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q78242

U.S. Application No.: 10/697,036

**AMENDMENTS TO THE CLAIMS** 

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (currently amended): A transformed cell in which a polynucleotide encoding an

osmosensing histidine kinase having no transmembrane region is introduced in a functional form

into a cell that is deficient in at least one hybrid-sensor kinase, wherein the cell is a bacterial cell,

a yeast cell, or a plant cell budding yeast cell.

2. (previously presented): The transformed cell according to claim 1, wherein the

polynucleotide complements the hybrid-sensor kinase deficiency.

3. (canceled).

4. (canceled).

5. (previously presented): The transformed cell according to claim 1, wherein the

osmosensing histidine kinase having no transmembrane region has a mutation that confers

resistance to any of a dicarboxyimide antifungal compound, an aromatic hydrocarbon antifungal

compound and a phenylpyrrole antifungal compound to the cell.

6. (previously presented): The transformed cell according to claim 5, wherein the

osmosensing histidine kinase having no transmembrane region has the amino acid sequence of

SEQ ID NO: 13.

7.

(currently amended): The transformed cell according to claim 1, wherein the

osmosensing histidine kinase having no transmembrane region is derived obtained from a plant-

pathogenic filamentous fungus.

2

Attorney Docket No.: Q78242

AMENDMENT UNDER 37 C.F.R. § 1.114(c) U.S. Application No.: 10/697,036

- 8. (previously presented): The transformed cell according to claim 1, wherein the polynucleotide encodes an osmosensing histidine kinase having no transmembrane region is obtained from *Botryotinia fuckeliana*.
- 9. (previously presented): The transformed cell according to claim 1, wherein the osmosensing histidine kinase having no transmembrane region has the amino acid sequence of SEQ ID NO: 1.
- 10. (previously presented): The transformed cell according to claim 1, wherein the polynucleotide has the nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO:14.
- 11. (withdrawn-previously presented): A method of assaying the antifungal activity of a substance, which comprises:

a first step of culturing the transformed cell as defined in claim 1 in the presence of a test substance:

a second step of measuring an amount of intracellular signal transduction from the osmosensing histidine kinase having no transmembrane region or an index value having the correlation therewith; and

a third step of assessing the antifungal activity of the test substance based on a difference between an amount of intracellular signal transduction or an index value having the correlation therewith measured in the second step and a control.

12. (withdrawn): The method of assaying according to claim 11, wherein the amount of intracellular signal transduction from the osmosensing histidine kinase having no

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q78242

U.S. Application No.: 10/697,036

transmembrane region or the index value having the correlation therewith is an amount of growth of the transformed cell.

13. (withdrawn): A method of searching an antifungal compound, which comprises selecting an antifungal compound based on the antifungal activity assessed in the assaying method as defined in claim 11.

14. (withdrawn): An antifungal compound selected by the searching method as defined in claim 13.

15.-22. (Canceled)